Industry Profile: India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50 percent of global demand for various vaccines, 40 percent of generic orders in the US, and 25 percent of all medications in the UK.
India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Over 80 percent of the antiretroviral drugs used globally to combat AIDS (Acquired Immuno Deficiency Syndrome) are supplied by Indian pharmaceutical firms. The pharmaceutical sector was valued at US$ 33 billion in 2017. The country’s pharmaceutical industry is expected to expand at a CAGR of 22.4 percent over 2015–20 to reach US$ 55 billion. India’s pharmaceutical exports stood at US$ 17.27 billion in 2017-18 and are expected to reach US$ 20 billion by 2020. Indian companies received 304 Abbreviated New Drug Application (ANDA) approvals from the US Food and Drug Administration (USFDA) in 2017. The country accounts for around 30 percent (by volume) and about 10 percent (value) in the US$ 70-80 billion US generics market. India’s biotechnology industry comprising bio-pharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics is expected to grow at an average growth rate of around 30 percent a year and reach US$ 100 billion by 2025. Biopharma, comprising vaccines, therapeutics, and diagnostics, is the largest sub-sector contributing nearly 62 percent of the total revenues at Rs 12,600 crore (US$ 1.89 billion).
Company Profile: The company is one of the leading pharma companies, majorly domestic concentrated businesses. Other than India, its key markets include Australia, the Philippines, Chile, and Kazakhstan. The Indian industry has 63% of its revenue from India. The company operates in gastrointestinal, anti-infective, analgesics, and Food supplements like vitamins and minerals. In all segments, it outperforms its peer majority due to its business mix. The company was also developing medicine for diabetes, cardiac patients, Brain illness, dermatitis, and growing segmentation. Its Us business also shows 13% revenue growth from FY 17 to FY 18.
Shareholding Pattern: BSE Data
Financial and Ratio : [table id=161 /]
Future Prospect: US FDA is one significant issue for many companies. Company’s increasing focus on Chronic/OTC segments and new launches in the key therapeutic segments, its domestic formulation business is likely to register robust growth. The company filled 18 ANDA and received 13 ANDA approval from USFDA. US business is also growing with double-digit growth.
